A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a ...
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...
News Medical on MSN1d
Vimseltinib gains FDA approval for treating tenosynovial giant cell tumorThe U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...
A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...
AZoLifeSciences on MSN7mon
Study Identifies Microproteins as Key Source of Tumor-Specific Antigens in Liver CancerHowever, these cancers constitute over 90% of liver cancer cases ... of cancer-specific long noncoding RNAs. Studies on clear ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback